Compared to other experimental therapies, treatment with the ADHD medication lisdexamfetamine resulted in the lowest risk of hospitalization and death among people with amphetamine addiction, researchers reported on… read more.
Subscribe for our mailing list
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.